Compare Five Below Inc (FIVE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Merck & Co., Inc. — how do they compare? Five Below Inc trades at $234.71 (market cap $13.01B), while Merck & Co., Inc. trades at $130.41 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 24.8× Five Below Inc's market cap, and Merck & Co., Inc. pays a 2.6% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.
| FIVE | MRK | |
|---|---|---|
Market Cap | $13.01B | $323.00B |
Sector | Consumer Staples | Health |
52-Week High | $247.71 | $131.84 |
52-Week Low | $131.94 | $77.60 |
Enterprise Value | $13.90B | $369.77B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) is trading at $244.37, up 5.73% with strong bullish momentum. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.22 exceeding expectations of $1.77. Technical indicators signal bullish sentiment, supported by positive moving averages. Revenue growth remains solid, projected to reach $5.1B in 2026, though net margins have compressed from 9.78% in 2022 to 6.54% in 2025. Analyst consensus is strongly bullish with 62% buy ratings and a $252.36 price target.
FIVE presents a compelling growth story with expanding revenue and strong institutional support. However, elevated valuation multiples (P/E 30.79) and compressed profit margins pose risks. The stock's proximity to 52-week highs suggests limited near-term upside without significant catalysts. Execution on store expansion and margin improvement will be critical for sustained outperformance.
Merck (MRK) trades at $130.45, up 1.46% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, though the P/E ratio of 104.74 reflects high valuation expectations. Recent acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while dividend payments of $0.85 per share provide income stability.
Outlook remains positive with a consensus price target of $139.90, implying 7.2% upside, supported by 67.6% analyst buy ratings. Key risks include integration challenges from acquisitions, patent expirations, and regulatory pressures. Earnings growth and pipeline advancements are critical for sustaining the current premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
